Clinical trials: Pancreatic Cancer, Resected
Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma
Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer
Treatment, Prospective, Assignment, Open Label, Single-center, Non-randomized Study An exploratory clinical trial of comparison of Nab-Paclitaxel combined with Gemcitabine and Gemcitabine combined with Tegafur for adjuvant…
- Conditions
- Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma, Stage IIA Pancreatic Adenocarcinoma, Stage IIB Pancreatic Adenocarcinoma
- Trial name
- NCT04216758
- Testing
- nab-paclitaxel, Gemcitabine, tegafur
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Obstructive Jaundice, Pancreatic Head Cancer
Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pancreaticoduodenectomy in Obstructive Jaundice
Pancreaticoduodenectomy (PD) is a complex surgical procedure commonly performed for tumors of the pancreatic head and periampullary region.
- Conditions
- Obstructive Jaundice, Pancreatic Head Cancer, Periampullary Neoplasms, Biliary Tract Neoplasms
- Trial name
- NCT07532759
- Testing
- PTCD Catheter Removal, PTCD Catheter Retention
- Volunteers
- 100 people
- Sponsor
- Xu'an Wang
Pancreas Neoplasm
Effects of Chewing Gum Against Postoperative Ileus
The purpose of this study is to determine whether the use of chewing gum effects postoperative ileus after pancreaticoduodenectomy
- Trial name
- NCT04768660
- Testing
- gum
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Assiut University
Pancreatic Cancer
A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer
Study Hypothesis: To estimate time to recurrence in pancreatic cancer patients treated with adjuvant erlotinib and gemcitabine. Combination therapy will be given for 4 months followed by single agent erlotinib for a total of 12…
- Trial name
- NCT00336700
- Testing
- Gemcitabine, Erlotinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert J. Zeh, III MD, FACS
Pancreatic Neoplasms, Surgical Procedure, Unspecified
Multivisceral Resection in Distal Pancreatectomy
The objective of the study is to evaluate the characteristics of the patients and the results of morbidity and mortality after distal pancreatectomy isolated or accompanied by multivisceral resection including cholecystectomy.
- Trial name
- ERPANDIS-MRV (NCT04317352)
- Testing
- MVR
- Where
- Spain
- Volunteers
- 435 people
- Sponsor
- Universidad de Extremadura
Pancreatic Head Cancer
The ARTERY FIRST Approach for Resection of Pancreatic Head Cancer
To show whether the artery first approach leads to equal or less rate of positive resection margins in pancreatic head cancer than the standard technique (ppWhipple only with standard Kocher's manoeuvre)
- Trial name
- Artery first (NCT01332773)
- Testing
- Artery first procedure, No artery first procedure
- Where
- Germany
- Volunteers
- 124 people
- Sponsor
- Heidelberg University
Pancreatic Cancer
Chemotherapy and Radiation Following Pancreatic Surgery
To describe the overall survival and disease-free survival in pancreatic cancer patients treated with adjuvant chemoradiation with cisplatin, continuous infusion 5FU and interferon alpha followed by gemcitabine.
- Trial name
- NCT00660270
- Testing
- Pancreatic Surgery, Radiation therapy, Cisplatin
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer, Malnutrition
Pancreatic Resection, Malnutrition and Readmission
The Whipple procedure is associated with increased readmission rates for infection, pancreatic leak, and failure to thrive/malnutrition.
- Trial name
- NCT01947166
- Testing
- Nestle Impact Advanced Recovery nutritional supplement
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Duke University
Pancreas Metastases, Colorectal Cancer
Pancreas Resection for Colorectal Metastasis: Retrospective Study
The aim of this study is to collect data from different centres to obtain a larger case series and enable a better definition of the outcomes after pancreatic metastasectomy from primary colorectal cancer.
- Trial name
- NCT05714475
- Testing
- Pancreas surgery
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini
Pancreatic Cancer
Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective, or whether chemotherapy is more effective…
- Trial name
- NCT00058201
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- 27 sites in Australia, Canada and 11 more
- Volunteers
- 1,030 people
- Sponsor
- Royal Liverpool University Hospital
Pancreatic Cancer, Perioperative/Postoperative Complications
Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection
RATIONALE: Drugs such as vapreotide may prevent complications following pancreatic resection. It is not yet known if vapreotide is more effective than no further therapy in preventing side effects of pancreatic resection.
- Trial name
- NCT00014651
- Testing
- vapreotide, conventional surgery
- Where
- 18 sites in United States
- Sponsor
- Mayo Clinic
Pancreatic Cancer, Cholangiocarcinoma
Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients
This study investigates the effects of oral protein supplements on the nutritional status and quality of life in elderly patients following standard pancreatic resection.
- Conditions
- Pancreatic Cancer, Cholangiocarcinoma, Intraductal Papillary Mucinous Neoplasm, Neuroendocrine Tumor
- Trial name
- NCT06570174
- Testing
- oral protein supplements
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Non Functioning Pancreatic Endocrine Tumor
Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors
Chromogranin A (CgA) is a glycoprotein with a molecular weight of 49 to 52 kDa produced by chromaffin cells of the adrenal medulla, enterochromaffin-like (ECL) cells, and endocrine cells of the stomach and pancreas, and it is the…
- Trial name
- CgA (NCT02759718)
- Testing
- Chromogranin A
- Volunteers
- 111 people
- Sponsor
- Asan Medical Center
Pancreatic Ductal Adenocarcinoma
Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer
The purpose of this clinical trial is to study an experimental drug called PTP-01 that is being used as an imaging agent to diagnosis pancreatic cancer.
- Trial name
- NCT01962909
- Testing
- PTP-01
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Virginia
Pancreas Cancer, Pancreas Neoplasm
The Role of the Human Microbiome in Patients After Pancreatic Resection.
The goal of this observational study is to classify patients that undergo pancreatic resection for presumed pancreatic or periampullary malignancy into high and low risk groups for postoperative complications based on…
- Conditions
- Pancreas Cancer, Pancreas Neoplasm, Pancreas Adenocarcinoma, Periampullary Cancer
- Trial name
- MiPac (NCT06381882)
- Testing
- Pancreatic resection
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- St. Antonius Hospital
Pancreatic Cancer
Randomized Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection
The purpose of this study is to help us learn what the best amount of fluid is that patients should receive during pancreas surgery.
- Trial name
- NCT01058746
- Testing
- restrictive perioperative fluid management, Liberal perioperative fluid management
- Where
- United States
- Volunteers
- 331 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
Evaluation of Complete microscopicE Resection Margin (R0) and Lymph Node Involvement After Standard Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular Pancreatosplenectomy
Resection with negative margins (R0) followed by adjuvant chemotherapy is today the standard of care and the only chance of cure for patients with pancreatic ductal adenocarcinoma (PDA).
- Trial name
- REMIND-01 (NCT03679169)
- Testing
- pancreatosplenectomy
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Institut Paoli-Calmettes
Pancreas Cancer, Quality of Life
Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial
Exercise during chemotherapy (CT) is a promising strategy to reduce fatigue and improve health-related quality of life (HRQoL). Exercise may also have beneficial effects on tumor outcome by decreasing insulin resistance…
- Trial name
- APACaPOp (NCT03400072)
- Testing
- Unsupervised APA program, Supervised APA program
- Where
- 15 sites in France
- Volunteers
- 252 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Pancreatic Ductal Adenocarcinoma
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic…
- Trial name
- NCT04969731
- Testing
- Immuncell-LC, Gemcitabine
- Where
- South Korea
- Volunteers
- 408 people
- Sponsor
- GC Cell Corporation
Pancreatic Tumor
Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor
This clinical trial is to evaluate the safety and impact on prognosis of personalized neoantigen peptide-based vaccines, which are based on next-generation sequencing and major histocompatibility complex affinity prediction…
- Trial name
- NCT03558945
- Testing
- Personalized neoantigen vaccine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.